Immune checkpoint therapy in non-small cell lung cancer

Cancer Journal (United States)

Volumn 22, Issue 2, 2016, Pages 81-91

  Marrone, Kristen A ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immuno oncology; Immunotherapy; Lung neoplasms immunology; Non small cell lung carcinoma

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEALTH CARE QUALITY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84969530888     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000178     Document Type: Review

References (62)

1. Lung Cancer. 2015. Available at: http://www.cancer.org/cancer/lungcancer/. Accessed November 15, 2015.
2. Clinical Practice Guidelines in Oncology (NCCN Guidelines): non-small cell lung cancer. 2015. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed November 11, 2015.
3. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
4. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity ofanti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366: 2455-2465.
5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
6. Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol. 2013;24:2875-2880.
7. Jansen RL, Slingerland R, Goey SH, et al. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother. 1992;12:70-73.
8. Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.
9. Scagliotti GV, Bironzo P, Vansteenkiste JF. Addressing the unmet need in lung cancer: the potential of immuno-oncology. Cancer Treat Rev. 2015; 41:465-475.
10. Derniame S, Vignaud JM, Faure GC, et al. Alteration of the immunological synapse in lung cancer: a microenvironmental approach. Clin Exp Immunol. 2008;154:48-55.
11. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.
12. Jadus MR, Natividad J, Mai A, et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunolog-ical intervention. Clin Dev Immunol. 2012;2012:160724.
13. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14:5220-5227.
14. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410-4417.
15. + T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer. 2010;69:355-360.
16. Pardoll DM. The blockade of immune checkpoints in cancer immunother-apy. Nat Rev Cancer. 2012;12:252-264.
17. Erfani N, Mehrabadi SM, Ghayumi MA, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012;77:306-311.
18. + T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389-395.
19. Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.
20. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046-2054.
21. Besse B, Johnson M, Janne PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;55(suppl 3):S716-S718 [abstract 16LBA].
22. Vansteenkiste J, Fehrenbacher L, Spira AI, et al. Atezolizumab mono-therapy vs docetaxel in 2 L/3 L non-small cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Eur J Cancer. 2015;55(suppl 3):S716-S718 [abstract 14LBA].
23. Spigel D, Chaft J, Gettinger S, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33 (suppl): abstract 8028.
24. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):aphase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
25. Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675, 206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27(suppl 15):abstract 8071.
26. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
27. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-2012.
28. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
29. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-567.
30. Rizvi N, Brahmer J, Ou S, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl): abstract 8032.
31. Gulley J, Spigel D, Kelly K, et al. Avelumab (MSB0010718C), ananti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol. 2015;33(suppl): abstract 8034.
32. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373:123-135.
33. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373: 1627-1639.
34. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;S0140-673601281-01287.
35. FDA expands approved use of Opdivo to treat lung cancer. 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm. Accessed November 1, 2015.
36. FDA expands approved use of Opdivo in advanced lung cancer. 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm. Accessed November 1, 2015.
37. Rizvi N, Shepherd F, Antonia S, et al. First-line monotherapy with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-L1 status. Int J Radiat Oncol. 2014;90:S31.
38. Antonia S, Brahmer JR, Gettinger S, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;35(suppl): abstract 8113.
39. Kanda S, Goto K, Shiraishi H, et al. Phase I study of anti-PD-1 antibody ONO-4538 (nivolumab) and chemotherapy in patients with advanced non-small-cell lung cancer. Ann Oncol. 2014;25(suppl 4):iv426-iv470[abstract 1326P].
40. Antonia S, Gettinger S, Chow L, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol. 2014;35(suppl): abstract 8023.
41. Rizvi NA, Antonia SJ, Shepherd FA, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Int J Radiat Oncol. 2014;90:S34.
42. Gettinger S, Chow LQ, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol. 2014;90:S34.
43. FDA approves Keytruda for advanced non-small cell lung cancer. 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm. Accessed November 1, 2015.
44. Papadimitrakopoulou V, Patnaik A, Borghaei H, et al. Pembrolizumab (Pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C. J Clin Oncol. 2015;33(suppl): abstract 8031.
45. Patnaik A, Socinski M, Gubens M, et al. Phase 1 study of pembrolizumab (Pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol. 2015;33(suppl): abstract 8011.
46. FDA grants breakthrough therapy designation for Genentech's investi-gational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer. Available at: http://www.gene.com/media/press-releases/14583/2015-02-01/fda-grants-breakthrough-therapy-designat. Accessed November 1, 2015.
47. Horn L, Spigel D, Gettinger S, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase IA study. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33(suppl): abstract 8029.
48. Spira A, Park K, Mazieres J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2 L/3 L NSCLC (POPLAR). J Clin Oncol. 2015;33(suppl): abstract 8010.
49. Liu S, Powderly J, Camidge D, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl): abstract 8030.
50. Creelan B, Chow L, Kim DW, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl): abstract 3047.
51. Antonia S, Goldberg SB, Balmanoukian A, et al. Phase IB study of MEDI4736, aprogrammed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol. 2015;33(suppl): abstract 3014.
52. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
53. Hellmann MD, Creelan BC, Woo K, et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann Oncol. 2014;25(suppl 4):iv429[abstract 1229PD].
54. Horn L, Herbst RS, Spigel D, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). J Thorac Oncol. 2014; 8(suppl 2): abstract M01801.
55. M.A. Postow. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book, 35 (2015) 76-83.
56. Garon EBGL, Rizvi N, et al. Antitumor activityofpembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol. 2014;25: abstract LBA43.
57. Soria JC, Gettinger S, Gordon M, et al. Biomarkers associated with clinical activity of PD-L1 blockade in non-small cell lung cancer patients (NSCLC): patients (pts) in a phase I study of MPDL3280A. Ann Oncol. 2014; 25(suppl 4): iv426-70[abstract 1322P]).
58. Callea M, Albiges L, Gupta M, et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res. 2015;3:1158-1164.
59. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2015:1-9.
60. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956.
61. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
62. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.